145 related articles for article (PubMed ID: 1949924)
1. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus.
Albrecht LM; Rybak MJ; Warbasse LH; Edwards DJ
DICP; 1991; 25(7-8):713-5. PubMed ID: 1949924
[TBL] [Abstract][Full Text] [Related]
2. Vancomycin serum protein binding determination by ultrafiltration.
Ackerman BH; Taylor EH; Olsen KM; Abdel-Malak W; Pappas AA
Drug Intell Clin Pharm; 1988 Apr; 22(4):300-3. PubMed ID: 3371190
[TBL] [Abstract][Full Text] [Related]
3. Supratherapeutic Vancomycin Concentrations Associated With Hypothermia in a Burn Patient.
Porter SA
J Burn Care Res; 2018 Oct; 39(6):1058-1063. PubMed ID: 29931313
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.
Rybak MJ; Albrecht LM; Berman JR; Warbasse LH; Svensson CK
Antimicrob Agents Chemother; 1990 May; 34(5):792-5. PubMed ID: 2360818
[TBL] [Abstract][Full Text] [Related]
6. Unbound fraction of vancomycin in intensive care unit patients.
Kees MG; Wicha SG; Seefeld A; Kees F; Kloft C
J Clin Pharmacol; 2014 Mar; 54(3):318-23. PubMed ID: 24000044
[TBL] [Abstract][Full Text] [Related]
7. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection.
Markowitz N; Quinn EL; Saravolatz LD
Ann Intern Med; 1992 Sep; 117(5):390-8. PubMed ID: 1503330
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
Kitzis MD; Goldstein FW
Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
Pharmacotherapy; 1998; 18(5):1069-74. PubMed ID: 9758317
[TBL] [Abstract][Full Text] [Related]
10. The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries.
Zokufa HZ; Solem LD; Rodvold KA; Crossley KB; Fischer JH; Rotschafer JC
J Burn Care Rehabil; 1989; 10(5):425-8. PubMed ID: 2793921
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin Tissue Pharmacokinetics in Patients with Lower-Limb Infections via In Vivo Microdialysis.
Housman ST; Bhalodi AA; Shepard A; Nugent J; Nicolau DP
J Am Podiatr Med Assoc; 2015 Sep; 105(5):381-8. PubMed ID: 26429605
[TBL] [Abstract][Full Text] [Related]
12. Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha 1-acid glycoprotein levels.
Morita K; Yamaji A
Ther Drug Monit; 1995 Apr; 17(2):107-12. PubMed ID: 7624896
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin pharmacokinetics in patients with severe burn injuries.
Dolton M; Xu H; Cheong E; Maitz P; Kennedy P; Gottlieb T; Buono E; McLachlan AJ
Burns; 2010 Jun; 36(4):469-76. PubMed ID: 19875238
[TBL] [Abstract][Full Text] [Related]
14. Factors impacting unbound vancomycin concentrations in different patient populations.
Oyaert M; Spriet I; Allegaert K; Smits A; Vanstraelen K; Peersman N; Wauters J; Verhaegen J; Vermeersch P; Pauwels S
Antimicrob Agents Chemother; 2015 Nov; 59(11):7073-9. PubMed ID: 26349820
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH
Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and cerebrospinal fluid (CSF) concentrations of vancomycin in pediatric patients undergoing CSF shunt placement.
Fan-Havard P; Nahata MC; Bartkowski MH; Barson WJ; Kosnik EJ
Chemotherapy; 1990; 36(2):103-8. PubMed ID: 2311439
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin-binding characteristics in patients with serious infections.
Li L; Miles MV; Lakkis H; Zaritsky AL
Pharmacotherapy; 1996; 16(6):1024-9. PubMed ID: 8947974
[TBL] [Abstract][Full Text] [Related]
20. Factors impacting unbound vancomycin concentrations in neonates and young infants.
Smits A; Pauwels S; Oyaert M; Peersman N; Spriet I; Saegeman V; Allegaert K
Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1503-1510. PubMed ID: 29770901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
